Efficacy and safety of rivaroxaban plus aspirin compared with aspirin alone in patients with peripheral arterial disease: a systematic review and meta-analysis
Muhammad Farhan, Syed Hassan Ali, Daniyal Khalid, Adina Kazmi, Dua Asim, Zoha Idrees, Muhammad Saim Siddiqui, Sudais Bin Sohaib, Muhammad Saad Khan, Muhammad Mohsin Khan, Abubakr Mahmoud · 2026
Read Efficacy and safety of rivaroxaban plus aspirin compared with aspirin alone in patients with peripheral arterial disease: a systematic review and meta-analysis by Muhammad Farhan, Syed Hassan Ali, Daniyal Khalid, Adina Kazmi, Dua Asim, Zoha Idrees, Muhammad Saim Siddiqui, Sudais Bin Sohaib, Muhammad Saad Khan, Muhammad Mohsin Khan, Abubakr Mahmoud (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13354395.txt.
Description
Muhammad Farhan leads a 2026 pooled analysis of rivaroxaban plus aspirin versus aspirin alone in peripheral artery disease. Aspirin is the base drug, yet clot risk stays high in the narrowed-leg-artery disease. Trials following PRISMA guidance were pooled with random-effects models, with bias and certainty graded by standard tools.
Six trials with 90,325 participants qualified. Dual therapy cut major cardiovascular events, with a risk ratio of 0.82, plus heart attacks at 0.87 and limb ischaemia at 0.68. Heart death and major amputation did not fall clearly. Major bleeding by TIMI rules rose at 1.41, though brain and fatal bleeding stayed similar. Net benefit favours dual therapy for many patients.
Catalog record
| CREATOR | Muhammad Farhan, Syed Hassan Ali, Daniyal Khalid, Adina Kazmi, Dua Asim, Zoha Idrees, Muhammad Saim Siddiqui, Sudais Bin Sohaib, Muhammad Saad Khan, Muhammad Mohsin Khan, Abubakr Mahmoud |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43370 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |